24. (Twice amended) A method of producing a therapeutic polypeptide *in vitro*, comprising incubating cells of a mammalian retinal pigment epithelial cell line in a biologically compatible medium such that the cell line produces the polypeptide, wherein the cells of the cell line is selected from the group consisting of hRPE-7, hRPE-116 and ARPE-19 and wherein the cells of the cell line comprise an expression vector comprising a polynucleotide coding for the polypeptide selected from the group consisting of BDNF, NT-4, CNTF, Axokine, IGF I, IGF II, TGFβ-II, Midkine, IL-1β, TNF, NGF, IL-2/3, ILF, IL-6, NTN, Neublastin, VEGF, GDNF, PDGF, LEDGF and PEDF.

37. (Twice amended) The cell line IO/JG2/1, deposited under I-1695 on April 18, 1996 in the Collection Nationale de Cultures de Micro-organismes held by the Insitut Pasteur, Paris France.

REMARKS

Claims 1, 10, 24, and 37 are currently pending in this application. Applicants have amended claims 1, 10, 24 and 37. These amendments do not constitute new matter.

Applicants have amended claims 1, 24 and 37 to correct various informalities. These amendments do not constitute new matter.

Applicants have amended claims 1, 10 and 24 to recite "consisting of" language rather than "comprising" language. These amendments do not constitute new matter.

Objections to the Specification

The Examiner has objected to the disclosure contending that "on page 21, lines 18-19, the statement regarding OX-43 expression in aortic EC does not agree with the data in Table 1." Specifically, the Examiner contend that it is there "stated that aortic endothelium expresses OX-43 antigen, however in Table 1 in the row labeled 'NON-EC CNS (OX43' and in the column labeled 'Aortic EC base', there is a negative sign." Applicants acknowledge this apparent